Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DASFREE: Treatment-free remission (TFR) after discontinuation of dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) and deep molecular response (DMR)
    Meeting Abstract

    Shah, N. P.; Garcia-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Luciano, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • A multicenter, randomized phase 3 study of asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 TKIs
    Meeting Abstract

    Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Allepuz, A.; Polydoros, F.; Bédoucha, V.; Aimone, P.; Réa, D.
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Combination of asciminib, a novel and specific BCR-ABL1 inhibitor, plus imatinib in previously treated chronic myeloid leukemia (CML) patients: Phase 1 study results
    Meeting Abstract

    Talpaz, M.; Cortes, J.; Lang, F.; Kim, D. W.; Réa, D.; Mauro, M. J.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib, a specific allosteric BCR-ABL1 inhibitor targeting the myristoyl-binding site, in patients with chronic myeloid leukemia (CML) carrying the T315I mutation
    Meeting Abstract

    Deininger, M. W.; Réa, D.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
    Review

    Branford, S.; Kim, D. D. H.; Apperley, J. F.; Eide, C. A.; Mustjoki, S.; Ong, S. T.; Nteliopoulos, G.; Ernst, T.; Chuah, C.; Gambacorti-Passerini, C.; more...
    Leukemia (2019)

    Fulltext@MSK | Save
  • A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer
    Journal Article

    Tavakkoli, M.; Wilkins, C. R.; Mones, J. V.; Mauro, M. J.
    Frontiers in Oncology (2019)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
    Journal Article

    Cortes, J. E.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Milojkovic, D.; le Coutre, P.; Garcia-Gutierrez, V.; Crescenzo, R.; more...
    Journal of Cancer Research and Clinical Oncology (2019)

    Fulltext@MSK | Save
  • DASFREE: An 18-month update of dasatinib discontinuation in patients with chronic myeloid leukemia in chronic phase and deep molecular response
    Meeting Abstract

    Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casare, M. T.; Pane, F.; more...
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia
    Review

    Mauro, M. J.
    Current Opinion in Hematology (2019)

    Fulltext@MSK | Save
  • Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia
    Correspondence

    Abruzzese, E.; de Fabritiis, P.; Trawinska, M. M.; Niscola, P.; Apperley, J. F.; Mauro, M. J.
    European Journal of Haematology (2019)

    Fulltext@MSK | Save